• News Ticker alerts

Biotech Amylin Pharmaceuticals is seeking a buyer, news services are reporting. In February, the company quietly rejected a $22 a share bid from Bristol-Myers Squibb. Corporate raider Carl Icahn, Amylin's third largest shareholder, sued the company, claiming that a corporate bylaw frustrates investors wanting a proxy fight. Amylin shares have risen 78% in the last year, and rose 54% on one day, March 28, when the Bristol bid was reported. Amylin has two diabetes drugs, Bydureon and Byetta.

  • News Ticker alerts

Comments

Sign in to comment

Join our
newsletter list

Enter to win $25 at Broken Yolk Cafe

Each newsletter subscription
means another chance to win!

Close